新型冠状病毒肺炎有创机械通气患者的气压伤:系统文献综述
该系统综述纳入13项研究、1814例有创机械通气的COVID-19 ARDS成人患者及493例非COVID-19对照。COVID-19患者中至少发生一次气压伤的比例为14.7%(合并估计16.1%,95%CI 11.8-20.4%),气胸合并估计10.7%(95%CI 6.7-14.7%),纵隔气肿合并估计11.2%(95%CI 8.0-14.3%)。发生气压伤的COVID-19患者死亡率为61.6%(95%CI 50.2-73.0%)。非COVID-19 ARDS对照气压伤合并估计5.7%(95%CI -2.1%至13.5%),提示COVID-19患者气压伤率可能更高。
要点
- COVID-19 ARDS有创通气患者气压伤合并发生率16.1%(95%CI 11.8-20.4%),约每6例中1例发生。
- 气胸合并发生率10.7%(95%CI 6.7-14.7%),纵隔气肿合并发生率11.2%(95%CI 8.0-14.3%)。
- 发生气压伤的COVID-19患者死亡率高达61.6%(95%CI 50.2-73.0%),预后极差。
- 非COVID-19 ARDS对照气压伤合并估计5.7%(95%CI -2.1%至13.5%),COVID-19患者气压伤率可能更高。
- 纳入研究为成人COVID-19 ARDS有创通气患者,排除病例报告、非ICU场景及儿科研究。
适用人群与场景
- 成人COVID-19相关ARDS需要有创机械通气并入住ICU的患者;排除病例报告、非ICU场景研究和儿科研究。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 有创机械通气的COVID-19 ARDS患者发生气压伤(气胸、纵隔气肿)后死亡率约61.6%,一旦出现需高度警惕并积极处理。
研究设计与关键结果
- 系统文献综述纳入13项研究,共1814例有创机械通气的COVID-19患者和493例非COVID-19患者。
- COVID-19患者中266/1814例(14.7%)发生至少一次气压伤,合并估计16.1%(95%CI 11.8-20.4%)。
- 气胸发生于132/1435例,合并估计10.7%(95%CI 6.7-14.7%);纵隔气肿发生于162/1432例,合并估计11.2%(95%CI 8.0-14.3%)。
- 发生气压伤的COVID-19患者死亡111/198例,合并估计61.6%(95%CI 50.2-73.0%)。
- 非COVID-19 ARDS对照气压伤31/493例(6.3%),合并估计5.7%(95%CI -2.1%至13.5%)。
证据类型、等级与局限
- 证据类型为系统文献综述,检索PubMed和Scopus,由两名研究者独立筛选和数据提取;未提及证据等级或推荐强度。
- 局限:纳入研究数量有限(13项),各研究报告率高度变异,非COVID-19对照合并估计95%CI跨零(-2.1%至13.5%),未提及纳入研究的设计类型及异质性来源。
对床旁实践的改变
- 对COVID-19 ARDS有创通气患者应保持对气压伤(气胸、纵隔气肿)的高度警惕,因发生率约1/6且合并气压伤者死亡率约60%。
- 该综述未提供通气参数目标或气压伤预防措施的具体推荐,不能据此改变通气策略设置。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: There are concerns of a high barotrauma rate in coronavirus disease 2019 patients with acute respiratory distress syndrome receiving invasive mechanical ventilation. However, a few studies were published, and reported rates were highly variable. We performed a systematic literature review to identify rates of barotrauma, pneumothorax, and pneumomediastinum in coronavirus disease 2019 acute respiratory distress syndrome patients receiving invasive mechanical ventilation.
DATA SOURCE: PubMed and Scopus were searched for studies reporting barotrauma event rate in adult coronavirus disease 2019 patients receiving invasive mechanical ventilation.
STUDY SELECTION: We included all studies investigating adult patients with coronavirus disease 2019 acute respiratory distress syndrome requiring mechanical ventilation. Case reports, studies performed outside ICU setting, and pediatric studies were excluded. Two investigators independently screened and selected studies for inclusion.
DATA EXTRACTION: Two investigators abstracted data on study characteristics, rate of pneumothorax, pneumomediastinum and overall barotrauma events, and mortality. When available, data from noncoronavirus disease 2019 acute respiratory distress syndrome patients were also collected. Pooled estimates for barotrauma, pneumothorax, and pneumomediastinum were calculated.
DATA SYNTHESIS: A total of 13 studies with 1,814 invasively ventilated coronavirus disease 2019 patients and 493 noncoronavirus disease 2019 patients were included. A total of 266/1,814 patients (14.7%) had at least one barotrauma event (pooled estimates, 16.1% [95% CI, 11.8-20.4%]). Pneumothorax occurred in 132/1,435 patients (pooled estimates, 10.7%; 95% CI, 6.7-14.7%), whereas pneumomediastinum occurred in 162/1,432 patients (pooled estimates, 11.2%; 95% CI, 8.0-14.3%). Mortality in coronavirus disease 2019 patients who developed barotrauma was 111/198 patients (pooled estimates, 61.6%; 95% CI, 50.2-73.0%). In noncoronavirus disease 2019 acute respiratory distress syndrome patients, barotrauma occurred in 31/493 patients (6.3%; pooled estimates, 5.7%; 95% CI, -2.1% to 13.5%).
CONCLUSIONS: Barotrauma occurs in one out of six coronavirus disease 2019 acute respiratory distress syndrome patients receiving invasive mechanical ventilation and is associated with a mortality rate of about 60%. Barotrauma rate may be higher than noncoronavirus disease 2019 controls.
参考来源
- Belletti A, Todaro G, Valsecchi G, et al. Barotrauma in Coronavirus Disease 2019 Patients Undergoing Invasive Mechanical Ventilation: A Systematic Literature Review. Crit Care Med. 2022. PMID: 34637421. doi:10.1097/CCM.0000000000005283
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。